Rheumatology
Addressing gaps in care and insights
Rheumatologic diseases affect an estimated 54 million patients in the U.S alone and represent a leading cause of disability. The introduction of innovative medicines continues to reduce patient burden of disease. Recognizing the mechanisms of action across these treatments is diverse, delivering the benefits to patients requires high quality research-driven insights on treatment effectiveness, gaps in care, and disease progression.
Rheumatology conditions are complex. Accessing data shouldn’t be.
Understanding the complexities of these systemic inflammatory diseases, and the factors that affect response to treatments, drives our focus on bringing a dynamic new approach to real world evidence generation to healthcare stakeholders.
Meet the largest Rheumatology data network in the U.S.
A comprehensive view of the patient journey from clinical development to the clinic
Bringing new treatments to market and delivering personalized care is challenging. Insights from real world data can expedite development and inform commercialization. OM1 purposefully built the largest rheumatology network in the U.S to deliver the longitudinal clinical data necessary to answer your most urgent questions.
1,200+Rheumatologists 700+Specialty practices |
• Axial Spondyloarthritis (Radiographic/Non-Radiographic) |
Sample conditions*
Every condition presents its own unique challenges and opportunities. Select one of our sample datasets above to explore some of the features.
RA patients with deep clinical data
7.8 yrs
Mean follow-up
SLE patients with deep clinical data
8 yrs
Mean follow-up
AxSpa patients with deep clinical data
8.2 yrs
Mean follow-up
PsA patients with deep clinical data
7.9 yrs
Mean follow-up
*Data counts as of Q3 2023 ©OM1 Rheumatology Specialty Area
Use Cases
USE CASE
Burden of illness – depression in RA patients
High cost and complexity of RA treatments necessitate full assessment of depression as part of RA treatment evaluation.
LEARN MORE
USE CASE
Understanding the role patient subtype plays in PsA treatment selection
Understanding the drivers of treatment choice in the real world to see if certain patient subtypes see greater use of specific, competitive treatments and which are favored for lines of therapy.
LEARN MORE
USE CASE
Understanding the role of race in treatment response in SLE
Understanding the effectiveness of hydroxychloroquine in the real world across specific racial subtypes with Systemic Lupus Erythematosus (SLE).
LEARN MORE
Award-Winning Research Team
Our team of award-winning researchers have authored hundreds of publications, including scientific posters, articles in peer-reviewed journals, white papers, and books.